Haluk H Eraksoy - Infectious Diseases

Author Information

Haluk H. Eraksoy is a distinguished researcher affiliated with the Department of Infectious Diseases and Clinical Microbiology at the Istanbul Faculty of Medicine, Istanbul University, located in Istanbul, Turkey. His work primarily revolves around infectious diseases, with a particular focus on clinical microbiology and epidemiology. Eraksoy holds a significant position in the scientific community due to his comprehensive research and contributions to the field.

Research Contributions

Haluk H. Eraksoy has made substantial contributions to the field of infectious diseases. His research includes the study of ventilator-associated pneumonia, COVID-19 patient outcomes in relation to vaccination status, and the treatment of multi-drug resistant infections. Notably, he has explored the biofilm formation in panresistant Klebsiella pneumoniae and the impact of C-reactive protein in infective endocarditis. Eraksoy has also investigated genetic factors in HIV infection and the response to antiretroviral therapy. His work is highly relevant in understanding the dynamics of infectious agents and the human immune response, particularly in the context of emerging pathogens like SARS-CoV-2.

Aliases

Haluk H. Eraksoy is recognized under various aliases, including H Eraksoy, H. Eraksoy, and Haluk Eraksoy. These variations may appear in different publications and databases.

Publication and Citation Metrics

Metric	Value
Citation Count	1479
H-index	19
Paper Count	117

Publications:

Risk Factors and Prognostic Predictors of VentilatorAssociated Pneumonia in a Tertiary Care Hospital

DOI: 10.5578/flora.20229906

Year: 2022

Comparison of the Clinical and Laboratory Findings and Outcomes of Hospitalized COVID-19 Patients who Were Vaccinated with Coronavac or Unvaccinated: An Analytical, Cross Sectional Study

DOI: 10.21203/rs.3.rs-1063869/v1

Year: 2022

Intrathecal Colistin Induced Chemical Meningitis in a Case of Multi-Drug Resistant Acinetobacter baumannii Meningitis

DOI: 10.36519/idcm.2022.98

Year: 2022

Biofilm formation of panresistant Klebsiella pneumoniae.

DOI: 10.2217/fmb-2021-0108

Year: 2022

The Impact of C Reactive Protein in Prediction of the Outcome in Infective Endocarditis

DOI: 10.36519/idcm.2021.42

Year: 2021

Frequency of CCR5-Δ32, CCR2-64I and SDF1-3'A alleles in HIV-infected and uninfected patients in Istanbul, Turkey.

DOI: 10.3855/jidc.12861

Year: 2021

Trends and factors associated with modification or discontinuation of the initial antiretroviral regimen during the first year of treatment in the Turkish HIV-TR Cohort, 2011–2017

DOI: 10.1186/s12981-020-00328-6

Year: 2021

First Report of SARS-CoV-2 Gamma Variant in Turkey

DOI: 10.36519/idcm.2021.43

Year: 2021

The effect of tocilizumab, anakinra and prednisolone on antibody response to SARS-CoV-2 in patients with COVID-19: A prospective cohort study with multivariate analysis of factors affecting the antibody response

DOI: 10.1016/j.ijid.2021.03.031

Year: 2021

Gastrointestinal and Abdominal Tuberculosis.

DOI: 10.1016/j.gtc.2021.02.004

Year: 2021

What Does Asymptomatic Mean?

What are the Symptoms of Cervical Cancer?

What is Acute Respiratory Distress Syndrome (ARDS)?

How Does the CDC Respond to Infectious Disease Outbreaks?

How Does Host Fatty Acid Biosynthesis Interact with Pathogens?

What are Future Directions for Schistosomiasis Research?

What is COVID-19?

What are Some Examples of Protein Targets in Pathogens?

How do emerging infectious diseases pose a threat?

How to Treat Rashes Caused by Infections?

Partnered Content Networks

Relevant Topics